current landscape and future directions for lower-risk mds treatment
Published 5 years ago • 571 plays • Length 1:39Download video MP4
Download video MP3
Similar videos
-
1:20
the current standard of care for patients with lower-risk mds
-
2:16
current and future treatment approaches for hr-mds
-
3:38
a new set of treatment options for low-risk mds
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
1:19
future directions in mds
-
1:04
the future of mds management
-
3:36
the genetic landscape of mds: how this is improving & impacting the development of therapies
-
1:16
state of the art: mds
-
1:14
real-world treatment patterns of patients with low-risk mds reinitiating esas
-
3:31
promising treatment options emerging for higher-risk mds & the value of clinical trials
-
1:12
hypomethylating agents for low risk mds
-
2:04
state-of-the-art treatment for hr-mds
-
0:56
the current treatment landscape in cll
-
1:06
the current state of the art in hr-mds and the need to improve treatment approaches
-
5:06
personalized therapy for mds: advancements and the future
-
1:19
the current state-of-the-art in pv and future outlooks
-
1:53
the current immunotherapeutic landscape for treatment of dlbcl
-
1:15
exploring the evolving treatment landscape of myelofibrosis